The R&D pipeline reflects our long-term commitment to driving change to defeat obesity, haemophilia, growth disorders and other serious chronic diseases
Facts and figures specific to our Research & Development organisation
How we report our financial, social and environmental performance
What guides the way we do business
How we contribute to the Sustainable Development Goals
Mads Krogsgaard Thomsen, CSO of Novo Nordisk, considers the potential of stem cell-based therapies to cure type 1 diabetes and other chronic diseases
Read Mads’ perspective
Want to find out why getting as close as possible to the real thing with insulin treatment matters to people with diabetes?
Go here
Features and points of view from Novo Nordisk and the society we serve
Explore our Perspectives
Subscribe to Perspectives
Read more about the issue
23 Jun 2018
